Showing results (1-10 of 80) with videos related to
Sort By:
Pageof 8
The Journal of Clinical Investigation|February 1, 1988
Platelet glycoproteins Ia, Ic, and IIa are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell typesK D Pischel, H G Bluestein, V L WoodsThe Journal of Experimental Medicine|August 1, 1986
Very late activation antigens (VLA) are human leukocyte-neuronal crossreactive cell surface antigensK D Pischel, H G Bluestein, V L WoodsThe Journal of Clinical Investigation|March 1, 1989
Antigenic polymorphism of human very late activation protein-2 (platelet glycoprotein Ia-IIa). Platelet alloantigen HcaV L Woods, K D Pischel, E D Avery, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1987
Use of the monoclonal antibody 12F1 to characterize the differentiation antigen VLA-2K D Pischel, M E Hemler, C Huang, et al.The Journal of Clinical Investigation|June 1, 1987
Polymorphism of lymphocyte function-associated antigen-1 demonstrated by a lupus patient's alloantiserumK D Pischel, S D Marlin, T A Springer, et al.Clinical and Experimental Immunology|February 1, 1979
Heterogeneous neurocytotoxic antibodies in systemic lupus erythematosusH G BluesteinThe Journal of Rheumatology. Supplement|September 1, 1988
Anatomic and genetic considerations in the pathogenesis of ankylosing spondylitisH G BluesteinProceedings of the National Academy of Sciences of the United States of America|August 1, 1978
Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosusH G BluesteinThe Journal of Experimental Medicine|August 1, 1974
Alloantiserum-mediated suppression of histocompatibility-linked Ir-gene-controlled immune responses. Suppressive effects of IgG fragments derived from alloantiseraH G BluesteinArthritis and Rheumatism|September 1, 1976
Lymphocytotoxic antibody activity in cryoprecipitates from serum of patients with SLEN J Zvaifler, H G BluesteinPageof 8